Gossamer Bio, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, HC Wainwright Forecasts (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) – HC Wainwright boosted their Q3 2024 earnings per share (EPS) estimates for Gossamer Bio in a report issued on Thursday, August 29th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.00 EPS and FY2028 earnings at $0.29 EPS.

A number of other brokerages have also recently weighed in on GOSS. Oppenheimer assumed coverage on Gossamer Bio in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $9.00 price objective for the company. The Goldman Sachs Group reissued a “buy” rating and set a $8.00 target price on shares of Gossamer Bio in a research note on Monday, June 17th. Finally, Wedbush reissued an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Trading Down 1.2 %

Shares of NASDAQ GOSS opened at $0.87 on Monday. Gossamer Bio has a twelve month low of $0.45 and a twelve month high of $1.60. The company has a current ratio of 8.21, a quick ratio of 8.21 and a debt-to-equity ratio of 2.42. The stock has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $0.94. The stock has a market capitalization of $196.21 million, a PE ratio of -0.82 and a beta of 1.93.

Insider Transactions at Gossamer Bio

In other Gossamer Bio news, CEO Faheem Hasnain acquired 372,000 shares of the stock in a transaction dated Friday, June 21st. The stock was acquired at an average cost of $0.67 per share, with a total value of $249,240.00. Following the transaction, the chief executive officer now owns 5,408,073 shares in the company, valued at approximately $3,623,408.91. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Algert Global LLC purchased a new stake in shares of Gossamer Bio in the 2nd quarter valued at about $75,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Gossamer Bio by 67.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after purchasing an additional 124,913 shares during the last quarter. NEA Management Company LLC lifted its holdings in shares of Gossamer Bio by 14.2% in the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Gossamer Bio by 170.8% in the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after purchasing an additional 2,103,766 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Gossamer Bio by 204.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock valued at $1,844,000 after purchasing an additional 1,375,000 shares during the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.